Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

Big Pharma fought to keep prices high

Big Pharma exploited patent laws to stifle competition amid Medicare price negotiations, according to a new report

Salon

As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs

A new generation of radiotherapies are redefining cancer care, offering the potential for a more powerful treatment with fewer side effects. It could become a mainstream therapy for the big "traditional" cancers that make the disease the leading cause of death worldwide, which is why Morgan Stanley forecast the radiopharma…

Barchart

Reeves should nail down UK AstraZeneca deal. A collapse would be embarrassing

Chancellor hopes to cut state aid for Speke vaccine plant to £40m. But pro-growth Treasury must not let project slip overseas

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Blow to AstraZeneca vaccine project as Reeves plans funding cuts

Chancellor reportedly seeking to cut £20m from the £65m promised by Hunt to Merseyside manufacturing plant

The Guardian - UK

The Guardian view on record payouts for CEOs: the way they live now

Editorial: The latest High Pay Centre report confirms the persistent and damaging culture of entitlement at the top of business

The Guardian - UK

Typical FTSE 100 CEO pay hits record high of £4.2 million—but U.S. peers still earn 3 times as much

AstraZeneca’s Pascal Soriot and Rolls Royce’s Tufan Erginbilgic were among the highest-paid FTSE 100 CEOs, but what they make still trails behind the average pay of S&P 500 CEOs.

Fortune

FTSE 100 chief executive pay reaches highest level on record

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca's breast cancer drug fails in late-stage trial test

Truqap, the breast cancer drug which was on trial has failed to meet its main goal, the drug manufacturer AstraZeneca said on Tuesday. It said that its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall…

The Times of India

1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

Barchart

Is the British Gas boss really worth £8.2m?

The share price recovery has been partly driven by the surge in wholesale energy prices, which is beyond his control

The Guardian - UK

TOI Health News Morning Briefing| AstraZeneca's anti-cancer drug withdrawn in India, preventing dehydration in 50s, signs of heatstroke, role of fish oil supplements in cardiovascular health and more

DCGI orders withdrawal of AstraZeneca's cancer drug due to potential adverse effects

The Times of India

India's drug regulator orders withdrawal of AstraZeneca's cancer drug due to potential adverse effects

The Drug Controller General of India (DCGI) has asked all state drug regulators to withdraw AstraZeneca's anti-cancer drug Olaparib tablets. This drug which is mostly used for the treatment of patients with gBRCA mutation and advanced ovarian cancer and breast cancer has potential adverse effects, DCGI has said.

The Times of India

Urgent call for breast cancer drug to stop women’s lives being cut short

Women with HER2-low incurable secondary disease in Scotland currently have access, while others across the UK do not

The Independent UK

Will AstraZeneca be the UK’s first £200bn company?

The former pharma laggard is in a race with Shell to be the first FTSE 100 stock to be valued at £200bn

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

FTSE 100 Live 21 May: Inflation in focus after index closes slightly down

Higher-than expected UK inflation figures disappointed the City today, with shares falling as the 2.3% Consumer Price Index reading dashed hopes of a June interest rate cut.

The Guardian - UK

AstraZeneca aims to nearly double revenues to $80bn by 2030

UK’s biggest drugmaker says it plans to launch 20 major new medicines before the end of the decade

Evening Standard

'New era of growth': AstraZeneca sets out bold plans for $80bn revenues by 2030

The growth will be fuelled by 20 new drugs that are set to launch this decade

The Times of India

TOI Health News Morning Briefing| A new side effect of AstraZeneca COVID vaccine found, how to prevent hypertension if you are genetically susceptible, immense health benefits jeera pani offer, why you must chew food 32 times and more

Another side effect linked with AstraZeneca COVID vaccine: All about VITT

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Tyson Fury and Mo Salah outearn Europe’s highest paid CEOs—but top U.S. execs trail only Cristiano Ronaldo's $260 million haul

Stellantis CEO Carlos Tavares had a compensation package worth $39.4 million in 2023, lower than any of the world's top 50 sports stars.

The Hindu

Doctors group raises concerns over Covishield vaccine side effects

A group of doctors under the banner of Awaken India Movement (AIM) have raised concerns over the side effects of Covishield vaccine in the wake of pharmaceutical giant AstraZeneca admitting in a U.K. court that its vaccine can cause blood clots in rare cases.

The Times of India

TOI Health News Morning Briefing| Woman alleges COVID vaccine disabled her, severity of FLiRT COVID variants, measles vaccine ineffective in babies born via C-section, how to spot dehydration in kids, wheat alternatives for diabetics and more

Woman claims AstraZeneca's COVID vaccine permanently disabled her

The Times of India

Vaccine trial patient claims was permanently disabled after taking AstraZeneca's COVID vaccine; here's what happened

Amidst growing concerns around the safety of COVID vaccines developed by AstraZeneca, a new claim has come to the fore. A 42 year old American woman has claimed that she was "permanently disabled" after taking AstraZeneca's COVID vaccine during the clinical trial process. She also claims that her disability was…

Barchart

Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks to fewer side effects for patients. Even a partial replacement for chemotherapy could make it a $140 billion market -…

The Times of India

Parents claim death due to Covishield, to file lawsuit against Serum Institute of India

Parents nationwide intend to sue Pune's Serum Institute of India (SII) and government officials responsible for the Covid vaccine rollout. They allege their children's deaths resulted from vaccine side effects. Parents of 8 victims from Kerala, Mumbai, Coimbatore, Hyderabad, Bengaluru, and Kapurthala. This action follows AstraZeneca's acknowledgment in a UK…

The Guardian - UK

AstraZeneca’s Covid vaccine is no more – but its remarkable success must not be forgotten

Although dogged by controversy, the firm’s coronavirus jab saved the lives of millions and helped avert humanitarian crises in nations unable to access costly alternatives

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

International Monetary Fund

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.